Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
The Weekly Roundup: September 2-6
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Abrocitinib Shows Promise for Prurigo Nodularis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Exploring Afamelanotide for Vitiligo: Insights into the CUV 105 Phase 3 Clinical Trial
Advanced Laser Eases Acne Scars, Melasma, and Wrinkles